AN OPEN-LABEL, MULTICENTER PHASE Ib STUDY OF THE SAFETY AND TOLERABILITY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) ADMINISTERED IN COMBINATION WITH BEVACIZUMAB AND/OR OTHER TREATMENTS IN PATIENTS WITH SOLID TUMORS

Protocol: 
AAAQ7567
Phase: 
I

AN OPEN-LABEL, MULTICENTER PHASE Ib STUDY OF THE SAFETY AND TOLERABILITY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) ADMINISTERED IN COMBINATION WITH BEVACIZUMAB AND/OR OTHER TREATMENTS IN PATIENTS WITH SOLID TUMORS

To evaluate the safety and tolerability of atezolizumab administered with bevacizumab in patients with HCC. To evaluate the safety and tolerability of atezolizumab administered with bevacizumab and FOLFOX in patients with gastric cancer. To evaluate the safety and tolerability of atezolizumab administered with nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer.

Are you Eligible? (Inclusion Criteria)

• Signed Informed Consent Form
• Women or men aged ≥ 18 years
• Able to comply with the study protocol, in the investigator’s judgment
• Availability at the site of tumor specimens in paraffin blocks (preferred)
or ≥ 20 unstained slides, with an associated pathology report, prior to study
entry

Specialty Area(s)

Trial Location

Herbert Irving Comprehensive Cancer Center
161 Fort Washington Ave.
Herbert Irving Pavilion
New York, NY 10032
United States